1 citations
,
June 1990 in “PubMed” 2% topical minoxidil is safe and reduces hair shedding in Chinese men with male pattern baldness.
1 citations
,
May 1990 in “Indian Journal of Dermatology, Venereology and Leprology” 1 citations
,
March 1990 in “Clinical Drug Investigation” 2% topical minoxidil can help reduce hair loss and promote hair growth in male pattern baldness.
1 citations
,
January 1988 Topical DHEA safely increases skin oil production.
1 citations
,
May 1987 in “The Lancet” Topical minoxidil may help hair growth by improving blood flow to hair follicles.
1 citations
,
November 1981 in “PubMed” No clear conclusion available.
1 citations
,
September 1977 in “JAMA” A man regrew hair after using a 2% fluorouracil treatment on his scalp.
June 2026 in “Homo Politicus (Academy of Humanities and Economics in Lodz)” The effectiveness of ingredients in anti-hair loss products varies, and clinical trials are crucial to determine their success.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study developed a chitosan-based minoxidil nanogel for improved topical delivery in treating alopecia. The optimized nanogel, created using ionic gelation and a Box–Behnken design, had a particle size of 135.4 nm, low polydispersity, high positive zeta potential, and 89.7% entrapment efficiency. It demonstrated skin-compatible pH, pseudoplastic rheological behavior, good spreadability, and physical stability. In vitro studies showed sustained drug release over 48 hours and better drug deposition compared to conventional minoxidil solutions, indicating its potential as an effective treatment for alopecia.
Topical finasteride is proving to be an effective treatment for androgenetic alopecia, showing similar efficacy to oral finasteride but with a reduced risk of systemic adverse effects. This makes it a promising alternative for individuals seeking to minimize potential side effects while treating hair loss.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Topical finasteride is proving to be an effective treatment for androgenetic alopecia, showing similar efficacy to oral finasteride but with a reduced risk of systemic adverse effects. This makes it a promising alternative for individuals seeking to minimize potential side effects while treating hair loss.
April 2026 in “Frontiers in Bioengineering and Biotechnology” Cellulose membranes heal venous leg ulcers faster than standard dressings.
April 2026 in “International Journal of Drug Delivery Technology” Topical prostaglandin analogues may improve hair density in androgenetic alopecia, but more research is needed.
April 2026 in “Mendeley Data” Topical hair loss treatments have a stronger placebo effect than systemic ones.
April 2026 in “Mendeley Data” Topical treatments for hair loss have a stronger placebo effect than systemic ones.
STS01 1% effectively promotes hair regrowth with minimal side effects.
April 2026 in “Journal of Pharmaceutical Innovation” Curcumin nanocrystal gel improves skin absorption and is safe and effective for topical use.
March 2026 in “Journal of Pakistan Association of Dermatologists” Low-dose oral minoxidil is more effective and convenient for treating male pattern baldness than topical minoxidil.
March 2026 in “Journal of Cosmetic Dermatology” Topical Stemoxydine improves hair density in androgenetic alopecia with few side effects.
March 2026 in “Mendeley Data” Placebo treatments can significantly affect perceived hair growth in androgenetic alopecia.
March 2026 in “Mendeley Data” Placebo treatments can significantly affect perceived hair growth in androgenetic alopecia.
March 2026 in “Preprints.org” The combined stem cell secretome in the skin care product effectively reduces inflammation and promotes tissue regeneration.
March 2026 in “Mendeley Data” Placebo treatments can improve hair growth and satisfaction in hair loss.
March 2026 in “Mendeley Data” Placebo treatments can improve hair growth and satisfaction in hair loss.
March 2026 in “International Journal of Dermatology” Topical finasteride effectively and safely improves hair growth in men with androgenetic alopecia.
Oral minoxidil may have more cardiovascular risks than topical minoxidil.
Topical latanoprost acid at 0.05% concentration improved hair growth in women with androgenetic alopecia.
Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific doses and precautions.
Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific doses and precautions.
Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific doses and precautions.